Montelukast Actavis 4mg. 5mg & 10mg
Actavis Ireland is pleased to announce the introduction of Montelukast Paediatric (4 mg and 5 mg) and Montelukast Actavis (10 mg) on the first day of patent expiry.
Delivering key products on Day One continues to be an important focus for Actavis Ireland and this latest launch - on 25th February - continues to underline Actavis’ position as the fastest growing pharmaceutical company on the Irish market¹.
Montelukast is GMS reimbursable and available from all wholesalers from February 25th.
For full prescribing information on the products mentioned on this page, please go to the Products section of this website
Notes: ¹ IMS December 2012